32.70MMarket Cap-599P/E (TTM)
0.777High0.756Low2.68KVolume0.760Open0.790Pre Close2.05KTurnover0.01%Turnover RatioLossP/E (Static)43.28MShares1.43052wk High0.70P/B26.14MFloat Cap0.51252wk Low--Dividend TTM34.60MShs Float121.980Historical High--Div YieldTTM2.67%Amplitude0.512Historical Low0.762Avg Price1Lot Size
Quince Therapeutics Stock Forum
Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)
Quince Therapeutics (Nasdaq: QNCX) announced the publication of Phase 3 ATTeST clinical trial data in The Lancet Neurology, evaluating EryDex for treating Ataxia-Telangiectasia (A-T). The study, involving 175 participants across 22 institutions in 12 countries, demonstrated a favorable safety pro...
$Quince Therapeutics (QNCX.US)$
I would wait to see what it does after the bell. Either way keep this on your watchlist. It will run at some point. Aquisition agreement and the chart is ripe for a run.
No comment yet